Wockhardt Limited
WOCKPHARMA
주식 순위
#4550
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical... Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine. Further, the company offers delivery devices for insulin, including Dispopen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.
주가
$20.75
시가총액
$3.37B
변동 (1일)
-1.38%
변동 (1년)
33.03%
국가
IN
거래 Wockhardt Limited (WOCKPHARMA)
카테고리
Healthcare
Wockhardt Limited (WOCKPHARMA)의 매출
Jun 2026 기준 매출 TTM: $393.32M
Wockhardt Limited의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $393.32M입니다. 2024년에 회사는 $339.40M의 수익을 올렸으며 이는 2023년의 $323.31M 대비 증가입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Wockhardt Limited의 수익 기록 (2004 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 2026 (TTM) | $393.32M | 10.84% |
| 2025 | $354.86M | 4.56% |
| 2024 | $339.40M | 4.97% |
| 2023 | $323.31M | -24.02% |
| 2022 | $425.51M | 15.02% |
| 2021 | $369.93M | -2.01% |
| 2020 | $377.51M | -26.48% |
| 2019 | $513.51M | -14.80% |
| 2018 | $602.74M | -1.45% |
| 2017 | $611.63M | -9.01% |
| 2016 | $672.19M | -6.41% |
| 2015 | $718.21M | -10.88% |
| 2014 | $805.87M | -22.17% |
| 2013 | $1.04B | 13.80% |
| 2012 | $909.89M | 8.10% |
| 2011 | $841.74M | -16.02% |
| 2010 | $1.00B | 35.33% |
| 2008 | $740.59M | 9.85% |
| 2007 | $674.18M | 72.85% |
| 2006 | $390.03M | 24.39% |
| 2005 | $313.56M | 9.96% |
| 2004 | $285.15M | 0.00% |
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| $2.54B | 544.77% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| $830.81M | 111.23% |
US
|
|
| - | - |
IT
|
